Zamarytė-Sakavičienė, Kristina
Commentary on the impact of the COVID-19 passports in LithuaniaItem type:Publication, research article[2023][S8][M004][2] ;Jankunas, Rimas ;Sakalauskas, Leonidas; ;Stakišaitis, DonatasHelmersen, MigleJournal of Infection. Elsevier, 2023, vol. 86, iss. 3., p. 78-7922Scopus© Citations 2 Discrepancies of Pediatric Data of BNT162b2 mRNA Covid-19 Vaccine in the Assessment Report of the European Medicines AgencyItem type:Publication, research article[2022][S4][M001,N010][3] ;Jankūnas, Rimas Jonas ;Jančiauskienė, Rasa; Stakišaitis, DonatasBiomedical Journal of Scientific & Technical Research. Biomedical Research Network, LLC, 2022, 42, 2., p. 33374-33376Severe cases of Covid-19 predominantly occur in the elderly and subjects with underlying conditions. However, it is a mild disease in most of the affected people, particularly children and adolescents. This paper comments on the Assessment Report of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) (herein further referred to as Assessment Report) on the data of pediatric study; the Assessment Report served as a basis for authorization of Comirnaty vaccine for active immunization to prevent Covid-19 in individuals 12 to 15 years of age. By the legislation of the European Union, Assessment Report is a key document for an opinion of EMA regarding marketing authorization. Opinion of EMA provides a background for a decision of the European Commission to place a medicinal product for human use on the market.
8 Off-label use of antipsychotic agents in dementia: evidence for the revision of the reimbursement policyItem type:Publication, research article[2019][S1][M001,M003,M005][5] ;Stakišaitis, Donatas; ;Lesauskaitė, VitaJankūnas, Rimas JonasTherapeutic Innovation & Regulatory Science. Thousand Oaks : Sage, 2019, vol. 53, no. 4., p. 549-553BACKGROUND: Harmonized requirements apply for the marketing authorization of medicinal products in the EU Member States. On the contrary, the national legislations on the drug reimbursement are not harmonized. The aim of this study was to find out if they are robust enough to ensure high standards of public health protection with focus on the symptomatic treatment of dementia in the elderly. METHODS: A computerized search of authorized therapeutic indications of haloperidol and trihexyphenidyl in the national databases of 8 EU member states and an analysis of the national legislation on reimbursement policies in Lithuania and Latvia was performed. RESULTS: There is a discrepancy in the decisions on the marketing authorization vs the reimbursement in Lithuania and Latvia (reimbursement of haloperidol and trihexyphenidyl for the off-label treatment of dementia). CONCLUSIONS: National legislation on the drug reimbursement in Lithuania and Latvia does not provide safeguards for public health at the same level as the marketing authorization does. Absence of a revision of former decisions in the light of new evidence is a critical weakness of the drug reimbursement in Lithuania and Latvia. Reimbursement for the off-label indications may pose a risk to public health.
8Scopus© Citations 2 Pharmacovigilance and principle of nonmaleficence in sex reassignmentItem type:Publication, research article[2012][S1][M001][7]; ; ; ; Medicina. Kaunas : Lietuvos sveikatos mokslų universitetas, 2012, t. 48, Nr. 11., p. 605-611Physicians are obliged to provide treatment that is consistent with their commitment to avoid or minimize harm (nonmaleficence) and their commitment to do good (beneficence). Therefore, if patient’s desires were contradictory to the primary aim of medicine, the doctor’s calling would require him/her to thoroughly analyze the cause of the disease and provide an adequate as well as ethical treatment rather than obediently follow patient’s requests. Yet, chemical and surgical sex reassignment is one of the areas where some physicians surrender to the desire of their patients instead of finding out what their real condition is and trying to manage it in a way the essence of medicine would require. The objective of this article was to provide specific pharmacovigilance search details for the evaluation of the current situation and the scientific background of the treatment of gender dysphoria and to analyze its conformity with one of the two main ethical principles of medicine – nonmaleficence. Literature retrieval was accessed through Medline (1979–2011) using the terms “gender dysphoria,” “replacement hormonal therapy,” and “pharmacovigilance.” The article concludes that hormonal and surgical interventions have not proven to be medically justified and could be harmful, not treating the cause, but resulting in irreversible disability. Thus, these interventions contradict the principle of nonmaleficence and goals of basic therapeutics and pharmacovigilance. They are not based on clinical trials and are lacking a thorough follow-up assessment.
5